Information Provided By:
Fly News Breaks for August 6, 2015
ELGX
Aug 6, 2015 | 06:58 EDT
JPMorgan analyst Christopher Pasquale upgraded Endologix to Overweight saying the risk/reward is skewed to the upside following the recent pullback in shares. The company's Nellix has potential to be a disruptive new entrant in the endovascular aneurysm repair market, Pasquale tells investors. He raised his price target for shares to $17 from $15.
News For ELGX From the Last 2 Days
There are no results for your query ELGX